Table 3 Association between −521T>C and −388A>G polymorphisms in SLCO1B1 gene and statin-induced adverse reactions risk
Polymorphism | Statin type | Genetic model | N | Effect estimate (95 % CI) | Z | P value | I 2 % | Phet | Effect model | Begg’s test | Egger’s test | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
z | P | t | P | ||||||||||
−521T>C | Statins | C vs T | 6 | 1.99 (1.20–3.29) | 2.69 | 0.007 | 86.90 % | <0.001 | R | 0.38 | 0.707 | 1.91 | 0.129 |
CC vs TT | 10 | 2.21 (1.41–3.47) | 3.45 | 0.001 | 55.20 % | 0.017 | R | 0.54 | 0.592 | 1.32 | 0.223 | ||
TC vs TT | 10 | 1.26 (0.96–1.65) | 1.69 | 0.091 | 75.80 % | <0.001 | R | 1.97 | 0.049 | 2.36 | 0.046 | ||
TC/CC vs TT | 8 | 1.85 (1.20–2.85) | 2.80 | 0.005 | 80.70 % | <0.001 | R | 1.11 | 0.266 | 2.15 | 0.075 | ||
CC vs TT/TC | 6 | 2.76 (1.73–4.39) | 4.27 | <0.001 | 13.60 % | 0.327 | F | 0.00 | 1.000 | 0.31 | 0.769 | ||
Additive | 8 | 1.76 (1.25–2.50) | 3.19 | <0.001 | 86.10 % | <0.001 | R | 0.87 | 0.386 | 2.97 | 0.025 | ||
Simvastatin | C vs T | 3 | 3.00 (1.39–6.48) | 2.80 | 0.005 | 77.90 % | 0.011 | R | 0.00 | 1.000 | 0.01 | 0.993 | |
CC vs TT | 5 | 3.62 (1.33–9.83) | 2.52 | 0.012 | 69.10 % | 0.012 | R | –0.24 | 1.000 | 1.06 | 0.367 | ||
TC vs TT | 5 | 1.58 (0.78–3.19) | 1.28 | 0.200 | 86.50 % | <0.001 | R | 1.22 | 0.221 | 2.07 | 0.130 | ||
TC/CC vs TT | 4 | 3.43 (1.80–6.52) | 3.76 | <0.001 | 59.60 % | 0.060 | R | 0.34 | 0.734 | 0.32 | 0.777 | ||
CC vs TT/TC | 3 | 5.98 (2.53–14.13) | 4.07 | <0.001 | 0.00 % | 0.453 | F | 1.04 | 0.296 | –2.06 | 0.288 | ||
Additive | 3 | 2.87 (1.67–4.94) | 3.81 | <0.001 | 52.80 % | 0.120 | R | 0.00 | 1.000 | –0.17 | 0.892 | ||
Atorvastatin | C vs T | 2 | 1.35 (0.58–3.15) | 0.69 | 0.491 | 0.00 % | 0.605 | F | – | – | – | – | |
CC vs TT | 3 | 1.49 (0.61–3.65) | 0.87 | 0.383 | 0.00 % | 0.941 | F | 0.00 | 1.000 | 0.23 | 0.858 | ||
TC vs TT | 3 | 1.23 (0.83–1.82) | 1.03 | 0.303 | 0.00 % | 0.635 | F | 0.00 | 1.000 | 0.52 | 0.697 | ||
TC/CC vs TT | 5 | 1.11 (0.82–1.52) | 0.69 | 0.492 | 0.00 % | 0.606 | F | 0.73 | 0.462 | 2.60 | 0.081 | ||
CC vs TT/TC | 2 | 1.38 (0.21,9.13) | 0.33 | 0.738 | 0.00 % | 0.803 | F | – | – | – | – | ||
Additive | 2 | 1.36 (0.60–3.05) | 0.74 | 0.460 | 0.00 % | 0.468 | F | – | – | – | – | ||
Rosuvastatin | CC vs TT | 1 | 1.13 (0.65–1.97) | – | – | – | – | – | – | – | – | – | |
TC vs TT | 1 | 0.90 (0.72–1.12) | – | – | – | – | – | – | – | – | – | ||
Additive | 1 | 0.95 (0.79–1.15) | – | – | – | – | – | – | – | – | – | ||
Pravastatin | TC/CC vs TT | 1 | 1.03 (0.41–2.57) | – | – | – | – | – | – | – | – | – | |
Cerivastatin | Additive | 1 | 2.45 (1.61–3.75) | – | – | – | – | – | – | – | – | – | |
−388A>G | Statins | TC/CC vs TT | 2 | 0.94 (0.79–1.13) | 0.63 | 0.526 | 40.10 % | 0.196 | F | – | – | – | – |
Additive | 2 | 0.91 (0.81–1.02) | 1.58 | 0.114 | 0.00 % | 0.649 | F | – | – | – | – | ||